| Literature DB >> 27001729 |
Sachin S Shivatare1,2,3,4, Shih-Huang Chang1,3, Tsung-I Tsai5, Susan Yu Tseng1, Vidya S Shivatare1, Yih-Shyan Lin4, Yang-Yu Cheng1, Chien-Tai Ren1, Chang-Chun David Lee1, Sujeet Pawar1,2, Charng-Sheng Tsai4, Hao-Wei Shih4, Yi-Fang Zeng4, Chi-Hui Liang1,5, Peter D Kwong6, Dennis R Burton5, Chung-Yi Wu1, Chi-Huey Wong1,5.
Abstract
A new class of broadly neutralizing antibodies (bNAbs) from HIV donors has been reported to target the glycans on gp120--a glycoprotein found on the surface of the virus envelope--thus renewing hope of developing carbohydrate-based HIV vaccines. However, the version of gp120 used in previous studies was not from human T cells and so the glycosylation pattern could be somewhat different to that found in the native system. Moreover, some antibodies recognized two different glycans simultaneously and this cannot be detected with the commonly used glycan microarrays on glass slides. Here, we have developed a glycan microarray on an aluminium-oxide-coated glass slide containing a diverse set of glycans, including homo- and mixed N-glycans (high-mannose, hybrid and complex types) that were prepared by modular chemo-enzymatic methods to detect the presence of hetero-glycan binding behaviours. This new approach allows rapid screening and identification of optimal glycans recognized by neutralizing antibodies, and could speed up the development of HIV-1 vaccines targeting cell surface glycans.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27001729 PMCID: PMC4806563 DOI: 10.1038/nchem.2463
Source DB: PubMed Journal: Nat Chem ISSN: 1755-4330 Impact factor: 24.427